← All trials
NCT03297606
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 6, 2017
- Primary completion
- Sep 30, 2021
- Completion date
- Sep 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 720
- Arms / groups
- 13 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- AstraZenecaCollaborator
- British Columbia Cancer AgencyStudy chair
- RocheCollaborator
- PfizerCollaborator
- Seattle GeneticsCollaborator
- University of TorontoStudy chair
- British Columbia Cancer AgencyOfficial
- Bristol-Myers SquibbCollaborator
- University of TorontoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.